Why build a patent portfolio?
Every year, various lists are published of the top patent filers or owners from the past year. For example, for US patent grants Harrity Analytics have recently published their...
Every year, various lists are published of the top patent filers or owners from the past year. For example,...
Read More
Use of prophetic examples in patent specifications
Prophetic examples, sometimes referred to as “paper”, “speculative”, “fictitious” or “hypothetical” examples, are examples that are sometimes included into a patent specification that describe experiments that have not yet...
Prophetic examples, sometimes referred to as “paper”, “speculative”, “fictitious” or “hypothetical” examples, are examples that are sometimes included into...
Read More
サノフィ対アムジェン紛争　オーストラリアの近況
この記事は最初に2024年8月13日に英語で公開されました 標題は、何年にもわたるもっとも重要な医薬品特許紛争の一つであり、世界中の関係者の注目を集めています。アムジェン（Ａｍｇｅｎ）のＰＣＳＫ９抗体特許に関するこの特許訴訟は、機能的および構造的に定義されている抗体クレームの有効性を評価する際に主要な法管轄区域が採用する多様な手法を浮き彫りにしてきました。 米国において、アムジェンの特許クレームは、最高巡回裁判所により実施可能性の欠如を理由として無効の判決を受けました。
この記事は最初に2024年8月13日に英語で公開されました 標題は、何年にもわたるもっとも重要な医薬品特許紛争の一つであり、世界中の関係者の注目を集めています。アムジェン（Ａｍｇｅｎ）のＰＣＳＫ９抗体特許に関するこの特許訴訟は、機能的および構造的に定義されている抗体クレームの有効性を評価する際に主要な法管轄区域が採用する多様な手法を浮き彫りにしてきました。 米国において、アムジェンの特許クレームは、最高巡回裁判所により実施可能性の欠如を理由として無効の判決を受けました。
Read More
Sanofi v Amgen dispute: Australian update
It’s one of the most consequential pharmaceutical patent disputes in years, one that is being closely watched by practitioners around the world. The patent litigation concerning Amgen’s PCSK9 antibody...
It’s one of the most consequential pharmaceutical patent disputes in years, one that is being closely watched by practitioners...
Read More
Australia second in cleantech growth – tips for in-house counsel
With a landscape so compatible with cleantech solutions, no wonder Australia is a hotbed for innovation. We discuss this and provide tips for IP professionals working in the sector.
With a landscape so compatible with cleantech solutions, no wonder Australia is a hotbed for innovation. We discuss this...
Read More
Skinny labelling in the Australian context: an overview
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be protected by several different patent claim formats, including method of...
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be...
Read More
IAM Patent 1000 2024
Spruson & Ferguson has once again been recognised in the 2024 IAM Patent 1000 rankings across the Asia-Pacific, with an outstanding result in multiple countries. We are delighted to announce the...
Spruson & Ferguson has once again been recognised in the 2024 IAM Patent 1000 rankings across the Asia-Pacific, with an outstanding...
Read More